Purchase this article with an account.
Daiju Iwata, Nobuyoshi Kitaichi, Akiko Miyazaki, Kazuya Iwabuchi, Kazuhiko Yoshida, Kenichi Namba, Michitaka Ozaki, Shigeaki Ohno, Kazuo Umezawa, Kenichiro Yamashita, Satoru Todo, Susumu Ishida, Kazunori Onoé; Amelioration of Experimental Autoimmune Uveoretinitis with Nuclear Factor-κB Inhibitor Dehydroxy Methyl Epoxyquinomicin in Mice. Invest. Ophthalmol. Vis. Sci. 2010;51(4):2077-2084. doi: https://doi.org/10.1167/iovs.09-4030.
Download citation file:
© ARVO (1962-2015); The Authors (2016-present)
Experimental autoimmune uveoretinitis (EAU), a Th1/Th17 cell-mediated autoimmune disease induced in mice, serves as a model of human endogenous uveitis. In this model, proinflammatory cytokines and various stimuli activate the transcriptional factor, nuclear factor-κB (NF-κB), in the retina. The therapeutic effect of the NF-κB inhibitor, dehydroxy methyl epoxyquinomicin (DHMEQ), was examined on EAU.
EAU was induced in B10.BR mice by K2 peptide immunization. DHMEQ (40 mg/kg/d) was administered daily by intraperitoneal injection. Clinical severity and histopathologic severity were assessed. Translocation of NF-κB p65 into the nucleus in EAU retina was assessed. T cells were collected from draining lymph nodes of the K2-immunized mice to examine antigen (Ag)-specific T-cell active responses and cytokine production in vitro.
Disease onset was significantly delayed in DHMEQ-treated mice (15.6 days) compared with untreated mice (12.6 days; P < 0.01). Histologic severity was significantly milder in DHMEQ-treated mice (score, 1.13) than in controls (score, 2.33; P < 0.05). DHMEQ suppressed the Ag-specific T-cell active responses and downregulated the productions of Th-1 type cytokines in vitro in a dose-dependent manner. Alternation was not observed in Th-2 type cytokines. Pretreatment of primed T cells or Ag-presenting cells with DHMEQ reduced T-cell activation and Th1/Th17 cytokine production. DHMEQ treatment suppressed the translocation of the NF-κB p65 subunit into the nuclei.
Systemic administration of DHMEQ suppressed NF-κB translocation in the retina, which might have reduced the inflammation of ocular tissues. DHMEQ-mediated regulation of NF-κB p65 could be a therapeutic target for the control of endogenous ocular inflammatory diseases.
This PDF is available to Subscribers Only